Nicolas Triballeau

102 Avenue Gaston Roussel
Romainville, 93230, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Design, Synthesis, and Biological Implications of Autotaxin inhibitors with a Three-Point lock binding mode.

Design, Synthesis, and Biological Implications of Autotaxin inhibitors with a Three-Point lock binding mode.

Journal: Bioorganic & medicinal chemistry

Published: February 06, 2025

Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases.

Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases.

Journal: Journal of medicinal chemistry

Published: September 28, 2021

Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis.

Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis.

Journal: Journal of medicinal chemistry

Published: March 15, 2021

Correction to Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2- a]pyridine Series of Autotaxin Inhibitors.

Correction to Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2- a]pyridine Series of Autotaxin Inhibitors.

Journal: Journal of medicinal chemistry

Published: April 20, 2018

Shedding Light on Important Waters for Drug Design: Simulations versus Grid-Based Methods.

Shedding Light on Important Waters for Drug Design: Simulations versus Grid-Based Methods.

Journal: Journal of chemical information and modeling

Published: March 01, 2018

Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.

Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.

Journal: Journal of medicinal chemistry

Published: July 22, 2017

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.

Journal: Journal of medicinal chemistry

Published: April 18, 2017

Reinvestigation of the Branimycin Stereochemistry at Position 17-C.

Reinvestigation of the Branimycin Stereochemistry at Position 17-C.

Journal: Organic letters

Published: February 06, 2016

Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic.

Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic.

Journal: Journal of medicinal chemistry

Published: November 08, 2014

Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.

Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.

Journal: Journal of medicinal chemistry

Published: September 11, 2012

Discovery of diarylhydantoins as new selective androgen receptor modulators.

Discovery of diarylhydantoins as new selective androgen receptor modulators.

Journal: Journal of medicinal chemistry

Published: August 18, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026